Aligos Therapeutics Inc (NASDAQ: ALGS)’s stock price has soared by 26.79 in relation to previous closing price of 4.48. Nevertheless, the company has seen a gain of 12.48% in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands.
Is It Worth Investing in Aligos Therapeutics Inc (NASDAQ: ALGS) Right Now?
ALGS has 36-month beta value of 2.75. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALGS is 4.02M, and currently, short sellers hold a 20.79% ratio of that float. The average trading volume of ALGS on May 13, 2025 was 182.38K shares.
ALGS’s Market Performance
ALGS stock saw an increase of 12.48% in the past week, with a monthly gain of 42.36% and a quarterly increase of -79.49%. The volatility ratio for the week is 16.54%, and the volatility levels for the last 30 days are 14.32% for Aligos Therapeutics Inc (ALGS). The simple moving average for the past 20 days is 11.63% for ALGS’s stock, with a -65.51% simple moving average for the past 200 days.
Analysts’ Opinion of ALGS
Many brokerage firms have already submitted their reports for ALGS stocks, with H.C. Wainwright repeating the rating for ALGS by listing it as a “Buy.” The predicted price for ALGS in the upcoming period, according to H.C. Wainwright is $75 based on the research report published on August 19, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALGS reach a price target of $3, previously predicting the price at $2. The rating they have provided for ALGS stocks is “Overweight” according to the report published on January 06th, 2023.
Jefferies gave a rating of “Buy” to ALGS, setting the target price at $3 in the report published on January 06th of the previous year.
ALGS Trading at -27.26% from the 50-Day Moving Average
After a stumble in the market that brought ALGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.86% of loss for the given period.
Volatility was left at 14.32%, however, over the last 30 days, the volatility rate increased by 16.54%, as shares surge +39.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.33% lower at present.
During the last 5 trading sessions, ALGS rose by +12.48%, which changed the moving average for the period of 200-days by -57.85% in comparison to the 20-day moving average, which settled at $5.09. In addition, Aligos Therapeutics Inc saw -85.74% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ALGS
Current profitability levels for the company are sitting at:
- -22.6 for the present operating margin
- 0.5 for the gross margin
The net margin for Aligos Therapeutics Inc stands at -33.26. The total capital return value is set at -1.84. Equity return is now at value -60.44, with -38.23 for asset returns.
Based on Aligos Therapeutics Inc (ALGS), the company’s capital structure generated -0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -9.64.
Currently, EBITDA for the company is -89.15 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 1.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.56.
Conclusion
To put it simply, Aligos Therapeutics Inc (ALGS) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
